22 results on '"Wand, O."'
Search Results
2. Exploring the Interplay of Dataset Size and Imbalance on CNN Performance in Healthcare: Using X-rays to Identify COVID-19 Patients.
- Author
-
Davidian M, Lahav A, Joshua BZ, Wand O, Lurie Y, and Mark S
- Abstract
Introduction: Convolutional Neural Network (CNN) systems in healthcare are influenced by unbalanced datasets and varying sizes. This article delves into the impact of dataset size, class imbalance, and their interplay on CNN systems, focusing on the size of the training set versus imbalance-a unique perspective compared to the prevailing literature. Furthermore, it addresses scenarios with more than two classification groups, often overlooked but prevalent in practical settings., Methods: Initially, a CNN was developed to classify lung diseases using X-ray images, distinguishing between healthy individuals and COVID-19 patients. Later, the model was expanded to include pneumonia patients. To evaluate performance, numerous experiments were conducted with varied data sizes and imbalance ratios for both binary and ternary classifications, measuring various indices to validate the model's efficacy., Results: The study revealed that increasing dataset size positively impacts CNN performance, but this improvement saturates beyond a certain size. A novel finding is that the data balance ratio influences performance more significantly than dataset size. The behavior of three-class classification mirrored that of binary classification, underscoring the importance of balanced datasets for accurate classification., Conclusions: This study emphasizes the fact that achieving balanced representation in datasets is crucial for optimal CNN performance in healthcare, challenging the conventional focus on dataset size. Balanced datasets improve classification accuracy, both in two-class and three-class scenarios, highlighting the need for data-balancing techniques to improve model reliability and effectiveness., Motivation: Our study is motivated by a scenario with 100 patient samples, offering two options: a balanced dataset with 200 samples and an unbalanced dataset with 500 samples (400 healthy individuals). We aim to provide insights into the optimal choice based on the interplay between dataset size and imbalance, enriching the discourse for stakeholders interested in achieving optimal model performance., Limitations: Recognizing a single model's generalizability limitations, we assert that further studies on diverse datasets are needed.
- Published
- 2024
- Full Text
- View/download PDF
3. Bronchiectasis in Subjects With Chronic Lymphocytic Leukemia.
- Author
-
Cohen D, Osadchy A, Cohen-Hagai K, Jarchowsky Dolberg O, Israeli-Shani L, Lishner M, Breslavsky A, Shitrit D, and Wand O
- Subjects
- Humans, Leukemia, Lymphocytic, Chronic, B-Cell complications, Bronchiectasis complications
- Published
- 2023
- Full Text
- View/download PDF
4. Intra-Cranial Arterial Calcifications in Hemodialysis Patients.
- Author
-
Fanadka F, Rozenberg I, Nacasch N, Einbinder Y, Benchetrit S, Wand O, Hod T, and Cohen-Hagai K
- Subjects
- Humans, Retrospective Studies, Renal Dialysis adverse effects, Risk Factors, Carotid Artery Diseases complications, Carotid Artery Diseases epidemiology, Vascular Calcification etiology, Atherosclerosis complications
- Abstract
Background and objectives : Vascular calcification is an integral part of atherosclerosis and has been reported to be an independent risk factor for cardiovascular diSsease. Intra Cranial Arterial Calcifications (ICAC) in maintenance hemodialysis (MHD) is highly prevalent. Materials and Methods : The aim of this retrospective study was to assess the predictors and outcomes of ICAC in MHD patients compared to a control group without kidney disease. A blinded neuroradiologist graded ICAC in brain imaging (computerized tomography) of MHD patients. Age- and sex-matched patients with normal kidney function served as the control group. Results : A total of 280 patients were included in the cohort; 140 of them were MHD patients with a mean ICAC score of 2.3 ± 0.2 versus a mean ICAC score of 1.4 ± 0.2 in the control group ( p < 0.01). More than 90% of hemodialysis patients in our study had some degree of ICAC. Lower albumin and higher phosphorus and CRP levels were associated with increased ICACs. The multivariate analysis model for predictors of 1-year mortality demonstrated an increased odds ratio for mortality as the ICAC score increased. Conclusions: ICAC is very prevalent among MHD patients and results not simply from passive deposition of calcium and phosphate but rather from complex and active processes involving inflammation and structural changes in blood vessels. ICAC independently predicted all-cause mortality and may help with risk stratification of this high-risk population.
- Published
- 2023
- Full Text
- View/download PDF
5. Outcomes of Hospitalized COVID-19 Patients: SARS-CoV-2 Variants and Vaccination Status Are Important Confounders of Results.
- Author
-
Wand O and Cohen-Hagai K
- Subjects
- Humans, Vaccination, SARS-CoV-2, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
6. Successful Therapy with Canakinumab and Mepolizumab for Familial Mediterranean Fever and Eosinophilic Pneumonia.
- Author
-
Wand O, Kimhi O, Israeli-Shani L, and Shitrit D
- Subjects
- Humans, Antibodies, Monoclonal, Humanized, Colchicine, Treatment Outcome, Familial Mediterranean Fever drug therapy, Pulmonary Eosinophilia drug therapy
- Published
- 2023
7. The Clinical Significance of LDL-Cholesterol on the Outcomes of Hemodialysis Patients with Acute Coronary Syndrome.
- Author
-
Cohen-Hagai K, Benchetrit S, Wand O, Grupper A, Shashar M, Solo O, Pereg D, Zitman-Gal T, Haskiah F, and Erez D
- Subjects
- Humans, Cholesterol, LDL, Clinical Relevance, Retrospective Studies, Renal Dialysis adverse effects, Inflammation drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Acute Coronary Syndrome complications, Acute Coronary Syndrome epidemiology
- Abstract
Background and objectives : Dyslipidemia is one of the most important modifiable risk factors in the pathogenesis of cardiovascular disease in the general population, but its importance in the hemodialysis (HD) population is uncertain. Materials and Methods : This retrospective cohort study includes HD patients hospitalized due to acute coronary syndrome (ACS) in the period 2015-2020 with lipid profile data during ACS. A control group with preserved kidney function was matched. Risk factors for 30-day and 1-year mortality were assessed. Results : Among 349 patients included in the analysis, 246 were HD-dependent ("HD group"). HD group patients had higher prevalence of diabetes, hypertension, and heart disease than the control group. At ACS hospitalization, lipid profile and chronic statin treatment were comparable between groups. Odds ratios for 30-day mortality in HD vs. control group was 5.2 (95% CI 1.8-15; p = 0.002) and for 1-year, 3.4 (95% CI 1.9-6.1; p <0.001). LDL and LDL < 70 did not change 30-day and 1-year mortality rates in the HD group ( p = 0.995, 0.823, respectively). However, survival after ACS in HD patients correlated positively with nutritional parameters such as serum albumin (r = 0.368, p < 0.001) and total cholesterol (r = 0.185, p < 0.001), and inversely with the inflammatory markers C-reactive protein (CRP; r = -0.348, p < 0.001) and neutrophils-to-lymphocytes ratio (NLR; r = -0.181, p = 0.019). Multivariate analysis demonstrated that heart failure was the only significant predictor of 1-year mortality (OR 2.8, p = 0.002). LDL < 70 mg/dL at ACS hospitalization did not predict 1-year mortality in the HD group. Conclusions : Despite comparable lipid profiles and statin treatment before and after ACS hospitalization, mortality rates were significantly higher among HD group. While malnutrition-inflammation markers were associated with survival of dialysis patients after ACS, LDL cholesterol was not. Thus, our study results emphasize that better nutritional status and less inflammation are associated with improved survival among HD patients.
- Published
- 2023
- Full Text
- View/download PDF
8. Real-Life Diagnostic Performance of the Hypersensitivity Pneumonitis Guidelines: A Multicenter Cohort Study.
- Author
-
Freund O, Hadad Y, Shalmon T, Wand O, Schneer S, Perluk TM, Kleinhendler E, Hershko T, Tiran B, Aviram G, Gershman E, Adir Y, Shitrit D, Bar-Shai A, and Unterman A
- Abstract
Hypersensitivity pneumonitis (HP) is a heterogeneous interstitial lung disease (ILD) that may be difficult to confidently diagnose. Recently, the 2020 ATS/JRS/ALAT HP diagnostic guidelines were published, yet data validating their performance in real-life settings are scarce. We aimed to assess the diagnostic performance of the HP guidelines compared to the gold-standard multidisciplinary discussion (MDD). For this purpose, we included consecutive ILD patients that underwent diagnostic bronchoscopy between 2017 and 2020 in three large medical centers. Four diagnostic factors (antigen exposure history, chest computed tomography pattern, bronchoalveolar lavage lymphocyte count, and histology results) were used to assign guidelines-based HP diagnostic confidence levels for each patient. A sensitivity analysis was performed, with MDD diagnosis as the reference standard. Overall, 213 ILD patients were included, 45 (21%) with an MDD diagnosis of HP. The guidelines' moderate (≥70%) confidence threshold produced optimal performance with 73% sensitivity for HP, 89% specificity, and a J-index of 0.62. The area under the receiver operating characteristic curve (AUC) for a correct guidelines-based diagnosis was 0.86. The guidelines had better performance for non-fibrotic than fibrotic HP (AUC 0.92 vs. 0.82). All diagnostic factors, except bronchoalveolar lavage lymphocyte count, were independent predictors for MDD diagnosis of HP in a multivariate analysis. In conclusion, the HP guidelines exhibited a good diagnostic performance compared to MDD diagnosis in real-life setting.
- Published
- 2023
- Full Text
- View/download PDF
9. Negative impact of high-performance flights on aviators with mitral valve prolapse.
- Author
-
Wand O, Gabbai D, Epstein Shochet G, Prokupetz A, Kats T, Ben-Ari O, Cohen-Hagai K, and Gordon B
- Subjects
- Male, Humans, Adolescent, Cohort Studies, Retrospective Studies, Mitral Valve Prolapse diagnostic imaging, Mitral Valve Prolapse epidemiology, Mitral Valve Prolapse complications, Pilots, Mitral Valve Insufficiency surgery
- Abstract
Background: While it appears not to affect healthy aviators' hearts, there are scarce data regarding the impact of high-performance flights on aviators with mitral valve prolapse (MVP)., Methods: A retrospective, comparative cohort study of military aviators with MVP. Subjects were categorized to either high-performance (jet fighter) or low-performance (transport and helicopter) aviators. The primary outcomes were the rates of mitral interventions and of adverse cardiovascular events since being an aircrew candidate and up to the end of flying career. Additional outcomes were echocardiographic measurements and the cumulative proportion of mitral valve interventions over time., Results: Of 33 male aviators with MVP, 18 were high-performance aviators. On average, follow-up started at age 18.5 years and lasted 27.8 ± 10.1 years. Baseline characteristics were similar between the study groups. Aviators of high-performance aircraft had increased rates of mitral valve surgery (33 % vs. 0, p = 0.021), MVP-related complications (39 % vs. 6.7 %, p = 0.046), and a higher incidence of mitral valve repair over time (p = 0.02). High-performance flight was associated with increased intraventricular septum thickness (IVS, 9.7 mm vs 8.9 mm, p = 0.015) and IVS index (p = 0.026) at the last echocardiographic assessment. High-performance aviators tended to develop worsening severity of mitral regurgitation., Conclusions: High-performance flight may be associated with an increased risk for valvular deterioration and need for mitral surgery in aviators with MVP., Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Chylothorax associated with sarcoidosis: a review of the literature.
- Author
-
Israeli-Shani L, King D, Epstein Shochet G, Shitrit D, and Wand O
- Abstract
Objective: To review the medical literature regarding chylothorax associated with sarcoidosis., Methods: A literature review of all reported cases of sarcoidosis-associated chylothorax, we included a novel case report to the analysis., Results: Of sixteen cases included in the study, 10 were women (62.5%), mean age 47±17years. In 6 subjects (37.5%) chylothorax was part of the initial presentation of sarcoidosis. Four subjects (25%) additionally suffered from lymphedema and chylous ascites, and one from chylous ascites only. Thoracic lymphadenopathy was reported for 13/16 subjects (81.3%) and lung parenchymal disease in 8/16 (50%). Compression of the thoracic duct was considered as a causative factor in 10 cases (62.5%). One case was attributed to granulomatous pleural inflammation, one to generalized lymphangiectasia, and no specific causative factors were identified in 4 remaining cases (25%). Overall mortality rate was 18.8% (3/16 subjects). Of note, all the subjects treated with corticosteroids survived., Conclusions: Since the association of sarcoidosis with chylothorax is exceedingly rare, alternative etiologies should be pursued even when chylothorax develops in a subject with preexisting sarcoidosis. However, the possibility of sarcoidosis should be entertained when other etiologies for a newly diagnosed chylothorax are ruled out. A multidisciplinary approach is required for optimal management, both for elucidating the diagnosis and for employing therapy, which could be multimodal. A trial of immunosuppressive therapy with corticosteroids should be considered.
- Published
- 2022
- Full Text
- View/download PDF
11. Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease.
- Author
-
Haim-Pinhas H, Yoskovitz G, Lishner M, Pereg D, Kitay-Cohen Y, Topaz G, Sela Y, Wand O, Rozenberg I, Benchetrit S, and Cohen-Hagai K
- Subjects
- Humans, Middle Aged, Aged, Aged, 80 and over, Aspirin therapeutic use, Retrospective Studies, Hemorrhage chemically induced, Hemorrhage complications, Primary Prevention methods, Platelet Aggregation Inhibitors adverse effects, Cardiovascular Diseases, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic chemically induced
- Abstract
Chronic kidney disease is associated with an increased risk for cardiovascular and bleeding events. Data regarding the effectiveness and risks of aspirin therapy for primary prevention in the high-risk group of patients with chronic kidney disease are scant and controversial. This retrospective study included patients with chronic kidney disease. Participants were divided according to aspirin use. Outcomes included non-fatal cardiovascular events, major bleeding events and all-cause mortality. Among 10,303 patients, 2169 met the inclusion criteria and 1818 were included after 1:1 propensity-score matching. Our final cohort included patients with mean age of 73.4 ± 11.6 years, estimated glomerular filtration rate of 31.5 ± 10.5 ml/min/1.73m
2 with follow up of 4.9 ± 1.5 years. There were no significant differences in all-cause mortality and bleeding events (odds ratio = 1.03, confidence interval [0.62, 1.84], p = .58 and odds ratio = 1.09, confidence interval [0.65, 1.72], p = .87 respectively). The incidence of cardiovascular events was higher in aspirin users versus non-users on univariate analysis (p < 0.01) and was comparable after controlling for possible risk-factors (OR = 1.05, CI [0.61, 3.14], p = .85). Chronic aspirin use for primary prevention of cardiovascular disease was not associated with lower mortality, cardiovascular events or increased bleeding among patients with chronic kidney disease. Those results were unexpected and should prompt further research in this field., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
12. Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients.
- Author
-
Nacasch N, Cohen-Hagai K, Tayar N, Levian A, Rashid G, Benchetrit S, Neumark E, Wand O, Hod T, Rosman Y, Shashar M, Grupper A, and Shitrit P
- Abstract
Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were also compared, and the association between the humoral responses to both vaccines was evaluated. The cohort included 94 MHD patients who were vaccinated at least once for HBV and twice for COVID-19. Among the 94 patients, 28 (29.8%) did not develop protective titers to HBV. Hypertension, coronary heart disease, and heart failure were more common in non-responders. Among MHD patients, 85% had positive IgG anti-spike SARS-CoV-2 levels 6 months after two doses of BNT162b2 (Pfizer/Biotech) vaccine. Age and immunosuppressive therapy were the main predictors of humoral response to COVID-19 vaccine. We did not find any association between non-responders to HBV and non-responders to COVID-19 vaccine. There was no difference in IgG anti-spike titers between HBV responders and non-responders (505 ± 644 vs. 504 ± 781, p = 0.9) Our results suggest that reduced humoral response to hepatitis B is not associated with reduced response to COVID-19 vaccine. Different risk-factors were associated with poor immune response to HBV and to COVID-19 vaccines.
- Published
- 2022
- Full Text
- View/download PDF
13. Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccination-Results from a Serological Survey.
- Author
-
Zacks N, Bar-Shai A, Levi H, Breslavsky A, Maayan S, Evgenia T, Feitelovich S, Wand O, Schaffer M, Sherer Y, Givaty G, Tzurel Ferber A, Michael T, and Bilenko N
- Abstract
Background: SARS-CoV-2 is a novel human pathogen causing Coronavirus Disease 2019 that has caused widespread global mortality and morbidity. Since health workers in Israel were among the first to be vaccinated, we had a unique opportunity to investigate the post-vaccination level of IgG anti-S levels antibodies (Abs) and their dynamics by demographic and professional factors. Methods: Prospective Serological Survey during December 2020−August 2021 at Barzilai Medical Center among 458 health care workers (HCW) followed for 6 months after the second BNT162b2 vaccine dose. Results: Antibody levels before the second dose, and 30, 90 and 180 days after were 57.1 ± 29.2, 223 ± 70.2, 172.8 ± 73.3 and 166.4 ± 100.7 AU/mL, respectively. From GEE analysis, females had higher Abs levels (β = 26.37 AU/mL, p = 0.002). Age was negatively associated with Abs, with a 1.17 AU/mL decrease for each additional year (p < 0.001). Direct contact with patients was associated with lower Abs by 25.02 AU/mL (p = 0.009) compared to working with no such contact. The average decline rate overall for the study period was 3.0 ± 2.9 AU/mL per week without differences by demographic parameters and was faster during the first 3 months after vaccination than in the subsequent 3 months. Conclusions: All demographic groups experienced a decline in Abs over time, faster during the first 3 months. Findings of overall Abs lower in males, workers with direct contact with patients, and older workers, should be considered for policy-making about choosing priority populations for additional vaccine doses in hospital settings.
- Published
- 2022
- Full Text
- View/download PDF
14. Intravenous Alpha-1 Antitrypsin Therapy for Critically Ill COVID-19 Patients.
- Author
-
Wand O, Dahan D, Tov N, Epstein Shochet G, King DA, and Shitrit D
- Subjects
- Critical Illness therapy, Humans, COVID-19, alpha 1-Antitrypsin Deficiency complications, alpha 1-Antitrypsin Deficiency drug therapy
- Published
- 2022
15. The Diagnostic Yield of Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) in Respiratory Compromised Patients under General Anesthesia.
- Author
-
Levin VG, Romem A, Epstein Shochet G, Wand O, Dahan D, and Shitrit D
- Subjects
- Anesthesia, General adverse effects, Bronchoscopy adverse effects, Bronchoscopy methods, Endosonography, Humans, Lymph Nodes pathology, Retrospective Studies, Endoscopic Ultrasound-Guided Fine Needle Aspiration adverse effects, Endoscopic Ultrasound-Guided Fine Needle Aspiration methods, Lung Neoplasms diagnosis, Lung Neoplasms pathology
- Abstract
Background: Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is a frequently used method for obtaining tissue samples for the diagnosis of various respiratory conditions, including lung cancer staging. In most cases, EBUS-TBNA is performed under moderate sedation (MS). However, in cases of respiratory compromised patients, if this procedure is performed, it is conducted under general anesthesia (GA)., Objectives: To assess the diagnostic yield of EBUS-TBNA among respiratory compromised patients., Methods: Data of consecutive patients (n=191) who underwent EBUS-TBNA at our medical center between January 2019 and December 2019 were retrospectively analyzed. Respiratory compromised patients underwent GA and patients without respiratory compromise were mostly moderately sedated (MS). Characteristics, diagnostic yield, and complication rates were compared., Results: Diagnostic yield was similar between the two sedation modes (89% in GA group and 78% in the MS group, P = 0.11). The number of total samples obtained per procedure was significantly higher in the GA vs. the MS group (4.1 ± 2.1 vs. 2.1 ± 1.33, P < 0.01). The overall complication rate was 13% and 20.9% in the GA vs. the MS groups, respectively (P = 0.14), with the most frequent complication being minor bleeding. Interestingly, while the number of brushings, bronchoalveolar lavage, and endobronchial biopsy were similar, the percent of subjects who underwent transbronchial biopsy was significantly higher in the GA group (49% vs. 24.2%, P < 0.01)., Conclusions: EBUS-TBNA performed under GA among respiratory compromised patients is safe and has similar diagnostic yield to that of patients without a respiratory compromise.
- Published
- 2022
16. MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF).
- Author
-
Epstein Shochet G, Israeli-Shani L, Kains I, Wand O, and Shitrit D
- Subjects
- Acetylcholinesterase genetics, Adult, Aged, Case-Control Studies, Female, GPI-Linked Proteins genetics, Humans, Idiopathic Pulmonary Fibrosis genetics, Idiopathic Pulmonary Fibrosis pathology, Interleukin-6 metabolism, Male, Middle Aged, Polymorphism, Single Nucleotide, cdc42 GTP-Binding Protein metabolism, Idiopathic Pulmonary Fibrosis metabolism, MicroRNAs metabolism
- Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease that causes scarring of the lungs. The disease is associated with the usual interstitial pneumonia pattern, which was not yet fully recapitulated by an animal model. Therefore, the disease is considered 'human specific'. miRNA-608 is a primate specific miRNA with many potential targets, such CdC42 and Interlukin-6 (IL-6) that were previously implicated in IPF pathology., Objective: To test miR-608 expression and its targets in IPF patient samples., Methods: RNA was extracted from Formalin fixed paraffin embedded tissue sections (N = 18). miRNA-608 and Cdc42 and IL-6 levels were analyzed by qPCR. Acetylcholinesterase (AChE) is another target of miRNA-608. Its' rs17228616 allele has a single-nucleotide polymorphism causing weakened miR-608 interaction (C2098A). Thus, DNA was extracted from whole blood samples from 56 subjects with fibrosing interstitial lung disease and this region was sequenced for assessment of rs17228616 allele polymorphism., Results: miR-608 is significantly overexpressed in IPF samples in comparison with controls (p < 0.05). Cdc42 and IL-6 levels were lower in the IPF patient samples compared with control samples (p < 0.001 and p < 0.05, respectively). The frequency of the rs17228616 minor A-allele was 17/56 (30.4%) with all patients being heterozygous. This result is significant vs. the published Israeli cohort of healthy individuals, which reported 17% prevalence of this allele in healthy control volunteers (p = 0.01, OR = 2.1, CI 95% [1.19-3.9])., Conclusion: miR-608 is overexpressed in IPF patients. While the exact mechanism remains to be discovered, it could potentially promote fibrotic disease.
- Published
- 2021
- Full Text
- View/download PDF
17. The Profile of COPD Patients with Prolonged Hospitalizations: A Retrospective Analysis of 200 Hospital Admissions.
- Author
-
Abd El-Qader E, Israeli-Shani L, Epstein Shochet G, Dovrish Z, King DA, Dahan D, Wand O, and Shitrit D
- Subjects
- Age Distribution, Aged, Aged, 80 and over, Analysis of Variance, Chi-Square Distribution, Cohort Studies, Databases, Factual, Female, Hospital Mortality, Humans, Incidence, Israel, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive epidemiology, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Analysis, Disease Progression, Hospitalization statistics & numerical data, Length of Stay statistics & numerical data, Positive-Pressure Respiration methods, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive therapy
- Abstract
Background: Patients with severe chronic obstructive pulmonary disease (COPD) experience frequent exacerbations and need to be hospitalized, resulting in an economic and social burden. Although data exist regarding reasons of frequent hospitalizations, there is no data available about the impact on the length of stay (LOS)., Objectives: To characterize the causes of prolonged hospitalizations in COPD patients., Methods: A retrospective study was conducted of patients who were diagnosed and treated in the pulmonary department for severe COPD exacerbations. All patient demographic data and medical history were collected. Data regarding the disease severity were also collected (including Global Initiative for Obstructive Lung Disease [GOLD] criteria, pulmonologist follow-up, prior hospitalizations, and LOS)., Results: The study comprised 200 patients, average age 69.5 ± 10.8 years, 61% males. Of these patients, 89 (45%) were hospitalized for up to 4 days, 111 (55%) for 5 days or more, and 34 (17%) for more than 7 days. Single patients had longer LOS compared with married patients (48% vs. 34%, P = 0.044). Multivariate analysis showed that the number of prior hospital admissions in the last year was a predictor of LOS (P = 0.038, odds ratio [OR] = 0.807, 95% confidence interval [95%CI] = 0.659-0.988), as well as the use of non-invasive respiratory support by bilevel positive airway pressure (BiPAP) during the hospitalization (P = 0.024, OR = 4.662, 95%CI = 1.229-17.681)., Conclusions: Fewer previous hospitalizations due to COPD exacerbations and the need for non-invasive respiratory support by BiPAP were found as predictors of longer LOS.
- Published
- 2020
18. Role of Transbronchial Cryobiopsy in Interstitial Lung Diseases: An Ongoing Tale.
- Author
-
Wand O, Unterman A, Shochet GE, and Shitrit D
- Subjects
- Biopsy, Humans, Longitudinal Studies, Lung, Lung Diseases, Interstitial
- Published
- 2020
- Full Text
- View/download PDF
19. Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease.
- Author
-
Wand O, Fox BD, Shtraichman O, Moreh-Rahav O, and Kramer MR
- Subjects
- Adrenal Cortex Hormones therapeutic use, Aged, Aged, 80 and over, Biomarkers metabolism, Biopsy, Diagnosis, Differential, Humans, Immunoglobulin G4-Related Disease diagnosis, Immunoglobulin G4-Related Disease drug therapy, Immunoglobulin G4-Related Disease immunology, Lymphocyte Count, Lymphocytes drug effects, Lymphocytes immunology, Male, Pleural Effusion diagnosis, Pleural Effusion drug therapy, Pleural Effusion immunology, Predictive Value of Tests, Retrospective Studies, Tomography, X-Ray Computed, Treatment Outcome, Adenosine Deaminase metabolism, Immunoglobulin G4-Related Disease enzymology, Lymphocytes enzymology, Pleural Effusion enzymology
- Abstract
Objective: Immunoglobulin G4-related disease (IgG4-RD) is a recently described systemic disorder. Pleural effusion is considered an uncommon manifestation of the disease. We describe a case series of patients with IgG4-RD and clinically significant pleural effusions., Methods: A retrospective analysis of patients with histologically proven IgG4-RD treated for pleural effusion in our clinic., Results: We identified 4 male patients with pleural effusion caused by IgG4-RD. The effusions were lymphocytic exudates, with especially high protein concentrations. All patients had hyperglobulinemia, elevated serum immunoglobulin G (IgG) levels and elevated levels subclasses IgG1 and IgG4. In two patients, levels of adenosine deaminase (ADA) were measured in the effusion and were elevated (309 and 108 IU/L). Tuberculosis was excluded in both cases by pleural biopsy. Involvement of other organs by IgG4-RD was the rule, especially thoracic lymphadenopathy which was prominent in all patients. In all cases, effusion responded to corticosteroids therapy. One patient developed radiological findings compatible with rounded atelectasis during remission., Conclusions: IgG4-RD may cause an ADA-positive, lymphocytic exudate with a high protein concentration, characteristics resembling tuberculous effusion. Thoracic lymphadenopathy, hyperglobulinemia, and an increased total IgG, IgG1, IgG4 may suggest the diagnosis. Not previously described, IgG4-RD pleural inflammation may result in rounded atelectasis. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (2): 225-230) ., Competing Interests: The authors report no conflict of interest regarding this manuscript. The study was self-funded by the Pulmonary Institute of Rabin Medical Center., (Copyright: © 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.)
- Published
- 2020
- Full Text
- View/download PDF
20. Fatal consequences of therapeutic thoracentesis in patients with systemic sclerosis.
- Author
-
Sirotkin T, Natour A, Wand O, and Levy Y
- Abstract
Systemic sclerosis (SSc) is a systemic autoimmune disease, characterized by systemic fibrosis and involvement of visceral organs. Pulmonary complications are common and a leading cause of death. Pleural effusions, however, are rare. Thoracentesis is a common procedure, performed to reveal the cause of pleural effusion or to drain it and relieve dyspnea. Although generally considered a low-risk intervention, complications of thoracentesis can lead to increased morbidity and mortality. We describe three patients with SSc and symptomatic pleural effusion who required thoracentesis. All patients deteriorated shortly after the procedure and died. We assume that patients with SSc are at high-risk to develop complications after thoracentesis, most likely due to the low compliant lungs and the low elastance of the pleura. In this population, thoracentesis should be done with high caution, while measuring the pleural pressure - invasively, or with noninvasive surrogates. Further studies are required to determine mechanisms of the complication. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (3): e2020006) ., (Copyright: © 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.)
- Published
- 2020
- Full Text
- View/download PDF
21. Use of adenosine test for the exclusion of preexcitation syndrome in asymptomatic individuals.
- Author
-
Grossman A, Wand O, Matezki S, Kerner A, Assa A, and Glikson M
- Subjects
- Adolescent, Atrioventricular Block physiopathology, Humans, Male, Military Personnel, Pre-Excitation Syndromes physiopathology, Retrospective Studies, Adenosine, Electrocardiography, Pre-Excitation Syndromes diagnosis, Vasodilator Agents
- Abstract
Background: Resting electrocardiogram is a routine procedure for the identification of potentially fatal conditions, including preexcitation syndrome (PES). Intravenous adenosine is a sensitive and specific means of exposing inapparent pathways in such patients. Yet, it may not be sensitive when complete atrioventricular (AV) block is not achieved because a low dose of adenosine is used. We evaluated the yield of a high-dose adenosine test that achieved complete AV nodal block for unmasking inapparent pathway in a healthy population., Methods: We retrospectively reviewed all Israeli air force (IAF) academy candidates who were referred to adenosine test based on a cardiologist's suspicion of PES. The results of the adenosine test were recorded, including the adenosine dose required to achieve complete AV block. The medical records of the subjects were reviewed to identify any adverse cardiovascular outcome., Results: Fifty-nine subjects who underwent adenosine test were followed for 35.42 ± 24 months. Complete AV block was achieved in all subjects with an average adenosine dose of 22.51 ± 12.67 mg. None of the subjects had evidence of an inapparent pathway. All subjects completed military service without adverse outcomes., Conclusions: The vast majority of young patients with a short PR interval do not have evidence of an accessory pathway and have a favorable prognosis. Thus, the yield of adenosine test in young combat recruits is questionable. Yet, if there is no evidence of an accessory pathway while achieving complete AV block on adenosine test, the chance of an accessory pathway being present is probably extremely low., (©2011, Wiley Periodicals, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
22. Clinical, echocardiographic and humoral status of patients following repair of tetralogy of Fallot: comparison of the second to the first decade.
- Author
-
Wand O, Perles Z, Rein AJ, Algur N, and Nir A
- Subjects
- Adolescent, Adult, Analysis of Variance, Child, Child, Preschool, Echocardiography, Electrocardiography, Exercise Test, Female, Humans, Male, Natriuretic Peptide, Brain blood, Postoperative Complications blood, Postoperative Complications physiopathology, Pulmonary Valve Insufficiency blood, Pulmonary Valve Insufficiency diagnosis, Pulmonary Valve Insufficiency physiopathology, Statistics, Nonparametric, Tetralogy of Fallot blood, Tetralogy of Fallot physiopathology, Treatment Outcome, Postoperative Complications diagnosis, Tetralogy of Fallot surgery
- Abstract
Background: Surgical repair of tetralogy of Fallot may leave the patient with pulmonary regurgitation, causing eventual right ventricle dilatation and dysfunction. Predicting clinical deterioration may help to determine the best timing for intervention., Objectives: To assess whether the clinical and humoral status of patients in the second decade after repair of ToF is worse than that of patients in the first decade after repair., Methods: Twenty-one patients with repaired ToF underwent clinical assessment, electrocardiogram, echocardiogram and measurement of plasma B-type natriuretic peptide and N-terminal pro-BNP as well as the 6 minute walk distance test. Patients were divided into two groups: group A - less than 10 years after repair (n=10, age < 12 years old), and group B - more than 10 years after repair (n=11, age > 12 years old). The age at repair was similar in both groups., Results: In all but one patient the distance in the 6 min walk test was less than the minimum for age. RV end-diastolic volume and the 6 min walk test correlated with age. NT-proBNP levels were significantly higher in the ToF group compared to 26 healthy controls (P < 0.0001) and were inversely correlated with RV ejection fraction. Comparison of the two groups showed no difference in RV end-diastolic volume indexed for body surface area, pulmonary regurgitation severity, right or left ventricular myocardial performance index, RV ejection fraction, QRS duration, or 6 min walk indexed to minimum for age., Conclusions: In this group of patients with similar age at operation and pulmonary regurgitation severity, most clinical, echocardiographic and humoral parameters were not worse in the second decade after repair of ToF. These data suggest that very early pulmonary valve replacement may not be of benefit.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.